Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0Q4OW
|
|||
| Former ID |
DNCL002697
|
|||
| Drug Name |
Pixantrone
|
|||
| Synonyms |
Pixuvri (TN)
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Diffuse large B-cell lymphoma [ICD-11: 2A81; ICD-10: C83.3] | Phase 3 | [1], [2] | |
| Follicular lymphoma [ICD-11: 2A80] | Phase 3 | [1], [2] | ||
| Multiple sclerosis [ICD-11: 8A40] | Phase 3 | [1], [2] | ||
| Pediatric cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-C96; ICD-9: 140-229] | Phase 1 | [3] | ||
| Company |
Cell Therapeutics
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C17H19N5O2
|
|||
| Canonical SMILES |
C1=CC(=C2C(=C1NCCN)C(=O)C3=C(C2=O)C=NC=C3)NCCN
|
|||
| InChI |
1S/C17H19N5O2/c18-4-7-21-12-1-2-13(22-8-5-19)15-14(12)16(23)10-3-6-20-9-11(10)17(15)24/h1-3,6,9,21-22H,4-5,7-8,18-19H2
|
|||
| InChIKey |
PEZPMAYDXJQYRV-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 144510-96-3
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
10243500, 14801640, 29311813, 47207191, 50268815, 57344765, 103424027, 104381156, 109692982, 123393022, 125822854, 126644882, 126681869, 128906544, 131299096, 135089360, 137002674, 141851778, 162172211, 162223317, 164764466, 164779938, 175437690, 179323415, 187051845, 198945891, 198993081, 210274945, 210280583, 223659404, 224997157, 225144373, 226399140, 241035957, 251916789, 251918028, 251971287, 252216086, 252448477
|
|||
| ChEBI ID |
CHEBI:135945
|
|||
| ADReCS Drug ID | BADD_D01786 | |||
| SuperDrug ATC ID |
L01DB11
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | DNA topoisomerase II (TOP2) | Target Info | Modulator | [4] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7544). | |||
| REF 2 | ClinicalTrials.gov (NCT00088530) BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL). U.S. National Institutes of Health. | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 4 | Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.